PriceTargets.com logo

ASLAN Pharmaceuticals - ASLN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $76.00
  • Forecasted Upside: 12,566.67%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.60 As of 12/24/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for ASLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ASLAN Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASLN

Analyst Price Target is $76.00
▲ +12,566.67% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for ASLAN Pharmaceuticals in the last 3 months. The average price target is $76.00, with a high forecast of $80.00 and a low forecast of $72.00. The average price target represents a 12,566.67% upside from the last price of $0.60.

This chart shows the closing price for ASLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in ASLAN Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$72.00
4/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$72.00
4/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$72.00
3/18/2024HC WainwrightLower TargetBuy ➝ Buy$136.00 ➝ $72.00
3/13/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$120.00 ➝ $80.00
11/6/2023HC WainwrightReiterated RatingBuy ➝ Buy$136.00
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$136.00
8/14/2023Roth MkmReiterated RatingBuy ➝ Buy$120.00
4/28/2023HC WainwrightLower Target$160.00 ➝ $136.00
3/27/2023HC WainwrightReiterated RatingBuy$160.00
2/27/2023Piper SandlerLower TargetOverweight$160.00 ➝ $120.00
2/27/2023HC WainwrightLower TargetBuy$280.00 ➝ $180.00
9/16/2022Piper SandlerBoost TargetOverweight$120.00 ➝ $160.00
8/15/2022HC WainwrightLower TargetBuy$320.00 ➝ $280.00
6/23/2022HC WainwrightReiterated RatingBuy$320.00
5/23/2022HC WainwrightReiterated RatingBuy$320.00
5/23/2022Piper SandlerLower TargetOverweight$320.00 ➝ $120.00
12/7/2021HC WainwrightReiterated RatingBuy
10/5/2021BTIG ResearchReiterated RatingHold
9/28/2021HC WainwrightReiterated RatingBuy$320.00
8/9/2021HC WainwrightReiterated RatingBuy$320.00
7/15/2021HC WainwrightReiterated RatingBuy$320.00
7/9/2021Jefferies Financial GroupInitiated CoverageBuy$320.00
5/12/2021HC WainwrightReiterated RatingBuy$320.00
5/11/2021Piper SandlerLower Target$360.00 ➝ $320.00
3/17/2021HC WainwrightBoost TargetBuy$200.00 ➝ $320.00
1/12/2021HC WainwrightReiterated RatingBuy
7/14/2020HC WainwrightReiterated RatingBuy$200.00
5/12/2020HC WainwrightReiterated RatingBuy$200.00
3/19/2020HC WainwrightReiterated RatingBuy$200.00
3/19/2020Piper SandlerLower Target$320.00 ➝ $240.00
(Data available from 12/27/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
ASLAN Pharmaceuticals logo
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases. It has research collaboration agreement with Zenyaku Kogyo Co., Ltd. for the development and commercialization of eblasakimab in atopic dermatitis and all other indications in Japan. The company was founded in 2010 and is headquartered in Singapore.
Read More

Today's Range

Now: $0.60
Low: $0.60
High: $0.60

50 Day Range

MA: $0.60
Low: $0.60
High: $0.60

52 Week Range

Now: $0.60
Low: $0.48
High: $25.44

Volume

N/A

Average Volume

122,322 shs

Market Capitalization

$1.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of ASLAN Pharmaceuticals?

The following Wall Street sell-side analysts have issued reports on ASLAN Pharmaceuticals in the last twelve months: HC Wainwright, and Piper Sandler.
View the latest analyst ratings for ASLN.

What is the current price target for ASLAN Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for ASLAN Pharmaceuticals in the last year. Their average twelve-month price target is $76.00, suggesting a possible upside of 12,566.7%. Piper Sandler has the highest price target set, predicting ASLN will reach $80.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $72.00 for ASLAN Pharmaceuticals in the next year.
View the latest price targets for ASLN.

What is the current consensus analyst rating for ASLAN Pharmaceuticals?

ASLAN Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ASLN will outperform the market and that investors should add to their positions of ASLAN Pharmaceuticals.
View the latest ratings for ASLN.

What other companies compete with ASLAN Pharmaceuticals?

Other companies that are similar to ASLAN Pharmaceuticals include Bio-Path, Lixte Biotechnology, Biomerica, Aeterna Zentaris and Bionomics. Learn More about companies similar to ASLAN Pharmaceuticals.

How do I contact ASLAN Pharmaceuticals' investor relations team?

ASLAN Pharmaceuticals' physical mailing address is 83 CLEMENCEAU AVENUE 12-03 UE SQUARE, SINGAPORE U0, 239920. The company's listed phone number is 65-6817-9598 and its investor relations email address is [email protected]. The official website for ASLAN Pharmaceuticals is www.aslanpharma.com. Learn More about contacing ASLAN Pharmaceuticals investor relations.